CLAIMS

1. A pathogen-inactivated cryoprecipitate composition comprising fibrinogen for use in a therapy, wherein the pathogen-inactivated cryoprecipitate is stored for at least 1 day at room temperature after thawing and prior to infusion into a subject.

2. The pathogen-inactivated cryoprecipitate composition for use of claim 1, wherein the cryoprecipitate is stored for at least 1 day at between 20ºC and 25ºC after thawing and prior to infusion into a subject.

3. The pathogen-inactivated cryoprecipitate composition for use of claim 1 or claim 2, wherein the cryoprecipitate is stored for at least 3 days at between 2ºC and 25ºC after thawing and prior to infusion into a subject.

4. The pathogen-inactivated cryoprecipitate composition for use of claim 1 or claim 2, wherein the cryoprecipitate is stored for at least 5 days at between 2ºC and 25ºC after thawing and prior to infusion into a subject.

5. The pathogen-inactivated cryoprecipitate composition for use of any one of claims 1-4, wherein the cryoprecipitate is stored for up to 7 days at between 2ºC and 25ºC after thawing and prior to infusion into a subject.

6. The pathogen-inactivated cryoprecipitate composition for use of any one of claims 1-5, wherein the subject suffers from bleeding.

7. The pathogen-inactivated cryoprecipitate composition for use of claim 6, wherein the bleeding is associated with fibrinogen deficiency or massive hemorrhage.

8. The pathogen-inactivated cryoprecipitate composition for use of any one of claims 1-5, wherein the subject suffers from von Willebrand disease.

9. The pathogen-inactivated cryoprecipitate composition for use of any one of claims 1-8, wherein the pathogen-inactivated cryoprecipitate composition comprises at least 600 mg of fibrinogen.

10. The pathogen-inactivated cryoprecipitate composition for use of any one of claims 1-8, wherein the pathogen-inactivated cryoprecipitate composition comprises at least 750 mg of fibrinogen.

11. The pathogen-inactivated cryoprecipitate composition for use of any one of claims 1-8, wherein the pathogen-inactivated cryoprecipitate composition comprises at least 1500 mg of fibrinogen.

12. The pathogen-inactivated cryoprecipitate composition for use of any one of claims 1-11, wherein the plasma has been pathogen inactivated by photochemical inactivation.

13. The pathogen-inactivated cryoprecipitate composition for use of any one of claims 1-12, wherein the plasma has been pathogen inactivated by photochemical inactivation with a psoralen; optionally wherein the psoralen is amotosalen.

14. Use of a pathogen-inactivated cryoprecipitate composition comprising fibrinogen in the manufacture of a medicament for the treatment of bleeding, wherein the pathogen-inactivated cryoprecipitate is stored for at least 1 day at room temperature after thawing and prior to infusion into a subject, and wherein the pathogen-inactivated cryoprecipitate composition comprises at least 600 mg of fibrinogen.

15. The use of claim 14, wherein the pathogen-inactivated cryoprecipitate composition is as defined in any one of claims 1-13.

16. The use of claim 14 or claim 15, wherein the bleeding is associated with fibrinogen deficiency, or massive hemorrhage or von Willebrand disease.

17. The use of any one of claims 14-16, wherein the cryoprecipitate composition comprises cryoprecipitate prepared from at least about 550 mL and less than 650 mL of pathogen-inactivated plasma.

18. The use of any one of claims 14-17, wherein the cryoprecipitate composition comprises a first cryoprecipitate prepared from at least about 550 mL and less than 650 mL of pathogen-inactivated plasma and a second cryoprecipitate prepared from at least about

550 mL and less than 650 mL of pathogen-inactivated plasma, wherein the first and the second cryoprecipitates are combined prior to freezing for storage.

19. The use of claim 18, wherein the cryoprecipitate composition further comprises a third cryoprecipitate prepared from at least about 550 mL and less than 650 mL of pathogen-inactivated plasma, wherein the first, second, and third cryoprecipitates are combined prior to infusion.

20. The use of any one of claims 14-19, wherein the cryoprecipitate composition comprises cryoprecipitate prepared from plasma obtained from 2-6 donors.

21. The use of any one of claims 17-20, wherein the plasma has been pathogen inactivated by photochemical inactivation.

22. The use of claim 21, wherein the plasma has been pathogen inactivated by photochemical inactivation with a psoralen; optionally, wherein the psoralen is amotosalen.

23. The use of any one of claims 17-22, wherein the cryoprecipitate is prepared from plasma that has been pathogen-inactivated in a first container suitable for photochemical inactivation of the plasma under sterile conditions;
wherein the first container is coupled to a compound absorption device (CAD) such that the pathogen-inactivated plasma can be transferred from the first container to the CAD under sterile conditions;
wherein the CAD is coupled to one or more second containers, each of which is coupled to the CAD such that the pathogen-inactivated plasma can be transferred from the CAD to the one or more second containers under sterile conditions; and
wherein the cryoprecipitate is contained within a third container configured to be coupled to one or more second containers, such that the pathogen-inactivated plasma can be transferred from the CAD to the one or more second containers to the third container under sterile conditions, wherein the third container is suitable for freezing the pathogen-inactivated plasma followed by thawing of the pathogen-inactivated plasma under conditions that provide for the formation of the cryoprecipitate.

24. The use of any one of claims 17-23, wherein the pathogen-inactivated cryoprecipitate composition comprises at least 750 mg of fibrinogen.

25. The use of any one of claims 18-23, wherein the pathogen-inactivated cryoprecipitate composition comprises at least 1500 mg of fibrinogen.